Skip to main content
Explore URMC
menu

Chunkit Fung, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-0394

Office: (585) 275-5823

Fax: (585) 273-1042

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

I chose this specialty because of the many exciting new therapeutic options for patients with genitourinary cancers, as well as the opportunity to become an integral part of a team that cares for patients during one of their most difficult times.

As my patient, you can depend on me for compassion and dedication, in addition to an innovative and patient-centered approach to care. My research interests are clinical trials for genitourinary cancers and cancer survivorship research. During my free time, I enjoy running, hiking, cooking and travel.

Conditions I Treat

- Prostate cancer
- Bladder cancer
- Testicular cancer
- Kidney cancer
- Adrenal cancer

Professional Background

Dr. Chunkit Fung graduated Summa Cum Laude with Distinction in Research from Cornell University in 2000. He then went on to Medical School at the University of Pennsylvania in Philadelphia, PA and graduated with his M.D in 2004. He completed his internal medicine Internship and Residency from 2004 through 2007 at the Hospital of the University of Pennsylvania. He held the position of Instructor in the Department of Medicine from the University of Pennsylvania from 2007 to 2008 and subsequently completed his Fellowship in Hematology and Oncology at the Hospital of the University of Pennsylvania from 2008 to 2011. He also received a Master in Clinical Epidemiology in 2012 from the University of Pennsylvania School in Medicine. In July 2011, he came to the University of Rochester School of Medicine and Dentistry as an Assistant Professor in the Department of Hematology and Oncology. His clinical research interests are developing clinical trials to evaluate new therapies in Genitourinary Oncology and Cancer Survivorship Research.

Research

I am a medical oncologist specialized in genitourinary malignancy and an Assistant Professor of medicine with research interests in cancer control, particularly in the development, implementation, and dissemination of mHealth behavioral interventions to prevent and manage treatment- and cancer-related toxicities in cancer survivors, with a specific focus in cardiovascular complications from cancer treatment. Additionally, I am interested in developing clinical trials to evaluate new therapeutics for treatment of urologic malignancies.

Credentials

Specialties

  • Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

2004
MD | University of Pennsylvania School of Medicine

Post-doctoral Training & Residency

07/01/2008 - 06/01/2011
Fellowship in Hematology/Oncology at Hospital of the University of Pennsylvania

07/01/2005 - 06/30/2007
Residency in Internal Medicine at Hospital of the University of Pennsylvania

07/01/2005 - 06/01/2007
Internship in Internal Medicine at Hospital of the University of Pennsylvania

VIEW ALL expand_more

Awards

2020
Human Rights Campaign Leadership Award for Rising Star Gala Leaders

2019
Presidential Diversity Award Nominee, University of Rochester

2018 - 2018
Civic Leadership Award
Sponsor: US TOO Prostate Cancer Support Group
Location: Rochester, NY

2018
URMC Wilmot Cancer Institute, Hematology/Oncology Fellowship Training Program, Teacher of the Year 2017/2018

2016 - 2018
Empire Clinical Research Investigator Program Fellowship Grant

2016
Strong Star Certificate of Appreciation

2015
Strong Star Certificate of Appreciation

2014
Strong Star Certificate of Appreciation

2013
Strong Star Certificate of Appreciation

2012 - 2015
Wimot Cancer Center Research Fellowship
Sponsor: Wimot Cancer Center

2012
Strong Star Certificate of Appreciation

2012
Patient and Family Centered Care Award

2011
American Society of Clinical Oncology Trainee Travel Award
Sponsor: American Society of Clinical Oncology

2010
National Institute of Health Loan Repayment Program
Sponsor: National Institute of Health

2000
Summa Cum Laude with Distinction in Research
Sponsor: Cornell University

1999
Howard Hughes Medical Institute Undergraduate Research Scholarship
Sponsor: Howard Hughes Medical Institute

VIEW ALL expand_more

Clinical Trials

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer (NILE)

Lead Researcher: Chunkit Fung

This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra).

View Study Details

A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study),,A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)

Lead Researcher: Chunkit Fung

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

View Study Details

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Lead Researcher: Chunkit Fung

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

View Study Details

A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Lead Researcher: Chunkit Fung

TAR-200 is a drug-device product that continuously releases a chemotherapy drug (called gemcitabine) in the bladder over several days. The purpose of this study is to determine if TAR-200, when combined with a first-line treatment (a drug called nivolumab) is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC).

View Study Details

IGUB-16112 A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Lead Researcher: Chunkit Fung

The primary purpose of this research study is to assess how metastatic or surgically unresectable Urothelial Carcinoma with FGF/FGFR alterations responds to treatment with INCB054828. The other goals of the study are to determine how safe and well tolerated the study drug, INCB054828, is, and to obtain data to try and identify patients who would benefit most from INCB054828.

View Study Details

IGUP17020: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Lead Researcher: Chunkit Fung

If you participate in this study, you will be assigned at random to receive treatment with either an experimental drug (called rucaparib) or one of the following comparator treatments: abiraterone acetate, enzalutamide, or docetaxel. If you are assigned to receive comparator treatment, your study doctor will help determine which one of the three therapy options is most appropriate for you. Approximately two thirds of the patients will be assigned to receive treatment with rucaparib and one-third will be assigned to receive comparator treatment.

View Study Details

IGUP17014: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Lead Researcher: Chunkit Fung

This research study is divided into three phases: Screening Phase is performed to find out if you are eligible for the study. If you qualify, you will be enrolled into the study and begin treatment. Treatment Phase (continuous dosing with rucaparib) Follow-up Phase: Follow Up visit (28 days after your last dose of rucaparib) and long term follow-up approximately every 12 weeks

View Study Details

Publications

Journal Articles

9/30/2020
Trendowski MR, Wheeler HE, El Charif O, Feldman DR, Hamilton R, Vaughn DJ, Fung C, Kollmannsberger C, Einhorn LH, Travis LB, Dolan ME. "Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2020 Sep 30; Epub 2020 Sep 30.

8/2020
Kerns SL, Fung C, Fossa SD, Dinh PC, Monahan P, Sesso HD, Frisina RD, Feldman DR, Hamilton RJ, Vaughn D, Martin N, Huddart R, Kollmannsberger C, Sahasrabudhe D, Ardeshir-Rouhani-Fard S, Einhorn L, Travis LB. "Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors." . 2020 Aug 0; 4(4):pkaa022. Epub 2020 Mar 20.

6/2020
Milano MT, Dinh PC, Yang H, Zaid MA, Fossa SD, Feldman DR, Monahan PO, Travis LB, Fung C. "Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24?900 Survivors." . 2020 Jun 0; 4(3):pkaa017. Epub 2020 Mar 17.

Books & Chapters

2017
Chapter Title: Second Cancers
Book Title: Cancer: Principles & Practice of Oncology, 11th Edition
Author List: Fung, C., Bhatia, S., Allan, J.M., Oeffinger, K.C., Ng, A., Travis L.B.
Edited By: DeVita, V.T. Jr., Lawrence, TS., Rosenberg, S.A.
Published By: Wolters Kluwer Health 2017 in Philadelphia

2014
Chapter Title: Second Malignant Neoplasms and Cardiovascular Disease Among Testicular Cancer Survivors
Book Title: Testicular Cancer: Diagnosis and Clinical Management
Author List: Fung, C., Fossa SD, Travis LB
Edited By: Einhorn LH, Horwich A, Huddart R
Published By: Oxford: Blackwell Publishing 2014

2014
Chapter Title: Second Malignant Neoplasms Among Testicular Cancer Survivors
Book Title: EAU-ICUD Consultation on Medical Treatment of Urological Malignancies
Author List: Fung, C., Travis, LB, Warde
Edited By: Massard C, Zhou FJ, Fossa SD
Published By: EAU-ICUD 2014

VIEW ALL PUBLICATIONS